SMAD2 and cancer: Here, platelet TGFβ1 is a general driver of cancer cell epithelial-to-mesenchymal transition (EMT) via activation of the Smad2/3 and NF-kB pathways (273, 274), and of HCC growth both in vitro and in vivo, where it also suppresses cancer cell Krueppel-like factor 6 (KLF6) expression (275).